Hunter Champion, MD
Cardiovascular Disease · Columbus, GANPI 1285683755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,134,289 of the $1,451,144 with a category attached, or 78.2%. 42 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 43.9% of the total. 2025 is the largest year on record at $330,121, 2.3 times the $140,802 reported in 2019. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,068 payments — averaging $701.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$638K
- United Therapeutics Corporation$332K
- Scpharmaceuticals Inc.$175K
- Bayer$134K
- Merck$58K
- Lexicon Pharmaceuticals, Inc.$48K
- plus $67K from 36 others
Across 12 payments — averaging $13,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$156K
- Actelion Pharmaceuticals US, Inc.$4K
What the payments were for
- Consulting fees$108,1237%
- Speaking & faculty fees$1,134,28978%
- Travel & lodging$160,46211%
- Food & beverage$39,1583%
- Education$450%
- Other$9,0681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$576,784
- OPSUMIT$495,853
- FUROSCIX$173,243
- Adempas$119,979
- ORENITRAM$116,264
- TYVASO$110,978
- Kerendia$52,602
- Inpefa$47,067
- WINREVAIR$41,186
- REMODULIN$34,853
- XARELTO$20,592
- FARXIGA$11,907
- VYNDAQEL$9,775
- ONPATTRO$4,920
- NONE$3,737
- Repatha$248
- CardioMEMS HF System$133
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$126
- Inspire$125
- VERQUVO$125
How this compares
$1,451,144 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 1,254 | $15,855,959 |
| AdempasRiociguat | 1,077 | $14,859,560 |
| UptraviSelexipag | 474 | $9,961,319 |
| Tyvaso DpiTreprostinil | 223 | $5,165,047 |
| Orenitram ErTreprostinil Diolamine | 224 | $1,113,087 |
| EliquisApixaban | 761 | $777,760 |
| WinrevairSotatercept-Csrk | 32 | $454,899 |
| XareltoRivaroxaban | 385 | $362,193 |
| EntrestoSacubitril/Valsartan | 246 | $237,675 |
| FarxigaDapagliflozin Propanediol | 230 | $229,327 |
| FuroscixFurosemide | 21 | $138,518 |
| Ambrisentan | 36 | $96,762 |
| Repatha SureclickEvolocumab | 89 | $85,595 |
| JardianceEmpagliflozin | 57 | $54,607 |
| Repatha PushtronexEvolocumab | 45 | $45,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $637,638 | $25,817,2781,728 claims |
| BayerAdempas | $133,928 | $14,859,5601,077 claims |
| PfizerEliquis | $10,847 | $777,760761 claims |
| MerckWinrevair | $57,682 | $454,89932 claims |
| Johnson & JohnsonXarelto | $22,243 | $362,193385 claims |
| AstraZenecaFarxiga, Brilinta | $12,752 | $243,895251 claims |
| NovartisEntresto | $1,075 | $237,675246 claims |
| Scpharmaceuticals Inc.Furoscix | $174,753 | $138,51821 claims |
| Boehringer IngelheimJardiance | $224 | $54,60757 claims |
| Sanofi-aventis U.S. LLCMultaq | $359 | $32,10717 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $436 | $19,52528 claims |
| AmgenCorlanor | $613 | $6,59012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Columbus
- Hiren ShahColumbus$166K
- Akram IbrahimColumbus$37K
- Louis Verreault-JulienColumbus$31K
- Vikramjit ChhokarColumbus$18K
- Narendra SinghJohns Creek$1.6M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.